

DEEP KNOWLEDGE GROUP

“Knowledge” is Power
“Deep Knowledge” is Transcending Power

DEEP KNOWLEDGE GROUP OVERVIEW

Deep Knowledge Group is a consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, FinTech, GovTech, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, media, philanthropy and more.

Its subsidiaries include Deep Knowledge Ventures, Longevity.Capital, AI-Pharma.Capital, Longevity FinTech Company, Deep Knowledge Analytics, Aging Analytics Agency, NeuroTech Analytics, Biogerontology Research Foundation, Longevity Swiss Foundation, AI-Longevity Consortium at King's College London, and Longevity International UK - Secretariat for the UK All Party Parliamentary on Longevity.

The consortium's major projects and initiatives grew out of the initial activities of Deep Knowledge Ventures, which was active on so many fronts of high-technology and science driven domains that it made the decision to form dedicated subsidiaries for each of the specific domains it was involved in.

Deep Knowledge Ventures was founded in 2014 as a data-driven investment fund focused on the synergetic convergence of DeepTech, frontier technologies and renowned for the use of sophisticated analytical systems for investment target identification and due-diligence.

Major investment sectors include AI, Precision Medicine, Longevity, FinTech and InvestTech.

Major short-term interests include AI and DeepTech, with a long term strategic focus on Longevity and Precision Health.

- **Deep Knowledge Group values Knowledge above profit - a vision embedded in its very name and brand**
- **Deep Knowledge Ventures fund considers its analytical subsidiaries among its most precious assets, marshalling the fund toward a long-term strategic vision**
- **Analytical subsidiaries are the knowledge engines driving the investment strategy of Deep Knowledge Group, producing open-source and proprietary analytics and advanced BigData Visualization Solutions**

Our Analytical and Non-Profit Activities are powerful tools for efficient and productive engagement with Governments, Progressive Top-Tier Corporations, Industry Influencers, Media and wide range of other strategically relevant people and organizations.



DEEP KNOWLEDGE GROUP STRUCTURE

INVESTMENT FUNDS



Longevity Fintech Company



Longevity.Capital



Deep Knowledge Ventures



AI-Pharma.Capital

ANALYTICAL SUBSIDIARIES



Deep Knowledge Analytics



Aging Analytics Agency




GovTech Division



Pharma Division



NeuroTech Analytics



Deep Knowledge Group

NON PROFIT



Biogerontology Research Foundation



Longevity Swiss Foundation



Longevity Media Company



AI Longevity Consortium at King's College London

LongevityUK

Secretariat for UK All-Party Parliamentary Group on Longevity

DEEP KNOWLEDGE GROUP PARTNERS



**DMITRY
KAMINSKIY**

**GENERAL
PARTNER**

Dmitry Kaminskiy, based in London. He is an experienced Longevity industry investor and entrepreneur, founder of Deep Knowledge Ventures and Aging Analytics Agency since 2014.



ERIC KIHLMSTROM

**MANAGING
PARTNER**

Eric Kihlstrom, based in London, has 30+ years of delivering impactful innovation to multinational corporations as well as rapid growth start-ups.



**MARGARETTA
COLANGELO**

**MANAGING
PARTNER**


Margaretta Colangelo, based in San Francisco, has 30+ years experience in executive, founder and advisory positions in the IT-industry.



**STEFAN
HASCOET**

**MANAGING
PARTNER**

Stefan Hascoet, based in Geneva, is the Capital Markets Professional with 15+ years experience in investment products, derivatives & non-recourse lending facilities




KATE BATZ

**MANAGING
PARTNER**

Kate Blatz, based in San Francisco, is licensed to practice law in California and New York. Lawyer with 20 years experience as a Corporate Attorney.






FRANCO
CORTESE

LONGEVITY &
LIFESCIENCES

Franco Cortese has been active in the Longevity Industry for significant experience in both the commercial and non-profit sectors, and is the author of over a dozen scientific papers on the topic of Longevity



SERGEY
BALASANYAN

FINTECH &
WEALTHTECH

Sergey Balasanyan is the Investment and Banking professional with 10+ years expertise in FinTech, Venture Capital and Business Development.



ALEX
CRESNIOV

TECH & DATA
ANALYTICS

Alex Cresniov is Data Science professional with diverse background and significant experience in Tech and Data Analytics, with 15+ years experience.



DEEP KNOWLEDGE GROUP GEOGRAPHY



DEEP KNOWLEDGE GROUP WEBSITES

INVESTMENT FUNDS

Deep Knowledge Ventures	www.dkv.global
Longevity.Capital	www.longevity.capital
AI-Pharma.Capital	www.ai-pharma.capital
Longevity Fintech Company	www.longevity.finance

ANALYTICAL SUBSIDIARIES

Deep Knowledge Analytics	www.dka.global
Pharma Division of Deep Knowledge Analytics	www.ai-pharma.dka.global
Aging Analytics Agency	www.aginganalytics.com
Proprietary Analytics by Pharma Division	www.ai-pharma.dka.global/proprietary-reports
Upcoming Analytical Reports by Aging Analytics Agency	www.aginganalytics.com/2019-agenda
Proprietary Analytics by Aging Analytics Agency	www.aginganalytics.com/proprietary-analytics
NeuroTech Analytics	www.neurotech.com/

INTERACTIVE MIND MAPS

Artificial Intelligence Mind Maps	www.dka.global/interactive-mind-maps
Longevity IT-Platform with interactive Mind Maps	www.aginganalytics.com/interactive-dynamic-mind-maps

NON-PROFIT

Biogerontology Research Foundation	www.bg-rf.org.uk
Longevity Swiss Foundation	www.longevitysuisse.org
Longevity International UK	www.longevityinternational.org
All-Party Parliamentary Group for Longevity	www.appg-longevity.org
AI Longevity Consortium at King's College	www.ai-longevity.center

ANALYTICAL SUBSIDIARIES

*DEEP KNOWLEDGE
GROUP*

DEEP KNOWLEDGE GROUP ANALYTICAL SUBSIDIARIES



Deep Knowledge Analytics

Deep Knowledge Analytics is a deep tech analytical agency using multidimensional algorithms to produce advanced industrial reports on DeepTech and frontier technologies. An online analytics platform with interactive visuals updated in real-time was released early this year



Pharma Division

The Pharma Division of Deep Knowledge Analytics specializes in the production of the most comprehensive analytical reports on the topics of Artificial Intelligence, Drug Discovery, Data Science and Digital Health within the broader Pharma Healthcare Industry and intersection of AI and Pharma.



GovTech Division

The GovTech Division of Deep Knowledge Analytics focuses on producing sophisticated open-access and proprietary analytics that reveal factors driving the ongoing transformation of the global GovTech industry, main sectors to be changed, barriers to this process, and ways to overcome them.



Aging Analytics Agency

Aging Analytics Agency began producing reports before the industry emerged and it is exclusively focused on Longevity, Geroscience, AgeTech and Preventive Medicine. The company has been developing its methodology since 2015 and is the main source of market intelligence in the field.



NeuroTech Analytics

NeuroTech Analytics specializes in the production of open-access and commercial comparative analytics on the full scope of the global NeuroTech industry, ranging from brain-computer interfaces to implant technologies, neurostimulation and neuromodulation, and neuroplasticity-increasing apps.

Published / Q1 2019



Longevity Industry in California
Landscape Overview 2019



Longevity Industry in Singapore
Landscape Overview 2019



Longevity Industry in Israel
Landscape Overview 2019



Longevity Industry in UK
Landscape Overview 2019

Published / Q2 2019



Top-50 Women
Longevity Leaders



Top-100
Longevity Leaders



FemTech Healthcare Landscape
Overview Q1 2019



National Longevity Development
Plans: Global Overview 2019
(First Edition)


AGING ANALYTICS AGENCY UPCOMING ANALYTICS Q3 & Q4 2019



Global Longevity Governance Landscape Overview 2019




States at Risk / Anti GovTech Landscape Overview 2019




Advancing Digital Financial Industry / Next Generation Derivatives



AI for Drug Discovery Landscape Overview 2019 / Q3



Biomarkers of Longevity: Most Comprehensive and Minimum Required Panels of Biomarkers of Aging



AI in Asia Landscape Overview 2019 / Q3

AGING ANALYTICS AGENCY UPCOMING ANALYTICS Q3 & Q4 2019




Longevity Industry and the Microbiome
Landscape Overview 2019




Top-100 Supercentenarians



Metabesity & Longevity
USA Special Case Study



Longevity Industry in Switzerland
Landscape Overview 2019




Longevity Industry in Hong Kong
Landscape Overview 2019




Longevity Industry in Japan
Landscape Overview 2019


AGING ANALYTICS AGENCY UPCOMING PROPRIETARY ANALYTICS Q3 & Q4 2019



Precision Medicine Clinics
Landscape Overview 2019




Advancing Financial Industry
Longevity / AgeTech / WealthTech



Longevity Industry Comparative Analysis and
Classification Framework



Top-20 Leading Longevity Investors
Comparative Analysis




Defining Hype vs Reality
in the Longevity Industry



Enhanced analysis of Top-30
Leading Longevity Companies

DEEP KNOWLEDGE ANALYTICS PHARMA DIVISION: UPCOMING PROPRIETARY REPORTS Q3 & Q4 2019



Comparative Industry Analysis & Classification Framework



Pharma AI Stock Index



Top Analysts AI in Pharma



Declining Efficiency of R&D in Pharma Corporations




Top-20 AI in Drug Discovery Investors



Enhanced analysis of most promising AI-companies as the best investments targets for AI-Pharma Index Hedge Fund

DEEP MULTIDIMENSIONAL BENCHMARKING OF GLOBAL LONGEVITY INDUSTRY




Aging Analytics Agency has developed a sophisticated multidimensional analytical framework to benchmark the full scope of companies within the global Longevity Industry to identify the top-40 most promising Longevity companies distributed across 10 distinct market sectors, revealing the untapped bottom of the Longevity Industry iceberg. This analytical methodology is the data-driven foundation upon which Longevity.Capital's 2020 target portfolio is structured.

LONGEVITY 2.0: ADVANCED QUANTITATIVE INDUSTRY ANALYTICS REFINED OVER 5+ YEARS



BigData Analysis and Data Science Multi-Dimensional Frameworks

MULTI-LAYER ANALYTICAL FRAMEWORKS FOR FULL-SCOPE LONGEVITY COMPANY BENCHMARKING & VALIDATION








Machine Learning and Predictive Analytics Framework







INTERACTIVE MINDMAPS

*DEEP KNOWLEDGE
GROUP*

DEEP KNOWLEDGE GROUP INTERACTIVE MINDMAPS



DEEP KNOWLEDGE GROUP INTERACTIVE MINDMAPS / NEXT LEVEL PROTOTYPE



INVESTMENT FUNDS

*DEEP KNOWLEDGE
GROUP*




Deep Knowledge Ventures

Deep Knowledge Ventures is a leading data-driven investment fund focused on the synergetic convergence of DeepTech, frontier technologies and technological megatrends, renowned for its use of sophisticated analytical system for investment target identification and due-diligence. While it's major short-term interests are AI and DeepTech, it's long term vision is focused on Longevity and Precision Health. The fund has offices in London, Zurich, Geneva, San Francisco, Toronto, Hawaii, Edinburgh, and Hong Kong.



Longevity.Capital

Longevity.Capital is a hybrid investment fund specifically focused on the Longevity Industry, backed by seasoned professionals who have been active in both the investment banking and Longevity industries for 25+ years, long before the sector was recognized as a serious prospect by the overwhelming majority of investors. The fund structures its portfolio based on sophisticated industry intelligence and comparative analytics provided by the world-leading Longevity Analytics entity Aging Analytics Agency.



AI-Pharma.Capital

AI-Pharma Investment Fund is a hybrid investment fund focused on the AI in Pharma and Drug discovery sectors, backed by seasoned professionals who have been active in both the investment banking and AI for Drug Discovery industries for years, long before the sector was recognized as a serious prospect by the overwhelming majority of investors, and some of whom made their first investments into the sector in 2014. The Fund structures its portfolio based on industry intelligence and analytics by the Pharma Division of Deep Knowledge Analytics.

LONGEVITY.CAPITAL FUND OVERVIEW



Longevity.Capital is a hybrid investment fund specifically focused on the Longevity Industry, backed by seasoned professionals who have been active in both the investment banking and Longevity industries for 25+ years, long before the sector was recognized as a serious prospect by the overwhelming majority of investors. The fund structures its portfolio based on sophisticated industry intelligence and comparative analytics provided by the world-leading Longevity Analytics entity Aging Analytics Agency, which uses hundreds of quantitative and fact-based parameters to identify prospective investment targets for the fund, utilizing multidimensional analytical frameworks as complex as the industry itself.

AI-PHARMA.CAPITAL FUND OVERVIEW

Provides Liquidity Similar to Hedge Funds Combined With Venture Fund Style Objectives

Significantly de-risks the interests of LPs




Invests in the top 10% of companies in the Longevity Industry

Bets on the success of the entire industry, rather than the success of individual companies

AI-Pharma is a hybrid investment fund specifically focused on the AI in Pharma and Drug Discovery sector, backed by seasoned professionals who have been active in both the investment banking and AI for Drug Discovery industries for years, long before the sector was recognized as a serious prospect by the overwhelming majority of investors, and some of whom made their first investments into the sector in 2014. The fund structures its portfolio based on sophisticated industry intelligence and comparative analytics provided by the Pharma Division of Deep Knowledge Analytics, the world-leading source of market intelligence on the AI for Drug Discovery, Biomarker Discovery and Advanced R&D sector, and which uses hundreds of quantitative and fact-based parameters to identify prospective investment targets for the fund, utilizing multidimensional analytical frameworks as complex as the industry itself.



英科智能
Insilico Medicine



LONGEVITY FINTECH

*DEEP KNOWLEDGE
GROUP*

LONGEVITY FINTECH COMPANY OVERVIEW

Longevity FinTech Company

Longevity Industry focused UK financial technology company, is aiming to provide White Label AgeTech, Fintech and WealthTech solutions for Financial Institutions to be prepared for the Silver Tsunami Economy and adapt their infrastructure to satisfy needs of the Senior Generation.

Longevity Marketplace

Longevity Marketplace is The World's First Fully-Integrated Platform with access to a full, specialized end-to-end scope of advanced Longevity Products, Services and Knowledge




Longevity Banking Card


Longevity Card is a Banking Card, Acting as the Key to Unlock Access to the Longevity Club Ecosystem and Marketplace, Granting Users Specialised Longevity Health and Wealth Products, Services and Knowledge, and Aims to Improve Lives of the Senior Generation by Combining AgeTech and Traditional Banking Services

Longevity Club

The Longevity Club is building an end-to-end ecosystem for Longevity Commerce, offering a vast mobile and online marketplace where people can discover and save on health and wealth-related products, maximizing their Healthspan (healthy period of life), using the optimal configurations of cutting edge personalised, preventive therapeutics, diagnostics and prognostics, as well as their Wealthspan (period of financial stability) to achieve financial wellness over the course of extended healthy lifespans.








INVEST TECH NOVEL SOLUTIONS

*DEEP KNOWLEDGE
GROUP*



Breakthrough investment solutions for advanced DeepTech startups with illiquid assets, providing them with liquidity similar to traditional commodity assets, making them Tradeable and Bankable.

GOVERNMENT RELATIONS
NON-PROFIT INITIATIVES
STRATEGIC BRAND DEVELOPMENT

***DEEP KNOWLEDGE
GROUP***



Biogerontology Research Foundation

Biogerontology Research Foundation is a non-profit focused on longevity, disease treatment and precision prevention. It is actively involved in UK Longevity Policy, Politics and government initiatives. Its aim is to neutralize the economic burden of an Ageing population



Longevity Swiss Foundation

Longevity Swiss Foundation Engaged with members of the Swiss government in establishing a National Swiss Longevity Development Plan to extend life expectancy through the application of AI, working alongside Swiss financial institutions, making Switzerland a leader in Longevity, Precision Health and Biomedicine



AI-Longevity Consortium at King's College London

The Longevity AI Consortium will serve as a leading R&D hub and industry-academic hotspot for advanced AI-driven personalized preventive diagnostics, prognostics and therapeutics. The main concept of precision medicine is providing health care which is individually tailored to a person's genes, lifestyle and environment



Longevity Media Company

Longevity Media Company is a source of the latest Longevity news, from science to lifestyle and investment. We aim to expand through curating relevant news to the public and hosting conferences. We also offer partnership opportunities and consulting services tuned to the needs of investors and HNWI's

Our Non-Profit Activities are powerful tools for ethical and productive engagement with Governments, Progressive Top-Tier Corporations, Industry Influencers, Journalists and wide range of other relevant people and organizations.



Metabesity and Longevity:
USA Special Case Study.
Joint Project with Targeting
Metabesity 2019
Conference in Washington.
Policy Proposal to the US
Congress.



Proposal to the UK All Party
Parliamentary Group
on Longevity:
"National Strategy for Five
More Years of Healthy Life
Expectancy in the UK.




Response to the World
Health Organization's
"Decade of Healthy Aging:
2020 – 2030 Draft Zero
Action Plan"



Proposal to the United
Nations on Optimization of
International Longevity
Policy and Governance

AI LONGEVITY ECOSYSTEM

The Longevity AI Consortium serves as a leading R&D hub and industry-academic hotspot for advanced AI-driven personalized preventive diagnostics, prognostics and therapeutics. The main concept of precision medicine is providing health care which is individually tailored on the basis of a person's genes, lifestyle and environment. With the advances in genetics, artificial intelligence and the growing availability of health data, present an opportunity to make precise personalized patient care a clinical reality.



AI Companies - Service Providers for Next Generation AI (Deep Learning, GANs, etc.)

Financial Corporations - Insurance Companies and Pensions Funds Interested in New Uses of Life Data and Health Data

Medical/Healthcare Corporations - Clients Interested in Leveraging Unique AI Cloud-Based Services


NHS and NHS-X - Providers of Anonymized Health and Life Data for AI Longevity R&D

Universities and Academic Labs - Research Partners Interested in AI for Longevity

Doctors and Clinics - Clients Interested in Leveraging Unique AI Cloud-Based Services

Ageing Research at King's (ARK) has developed Europe's first Longevity AI Consortium in 2019, building upon the foundation it has already established ageing and longevity research to turn scientific innovations into clinical realities. King's College London is an ideal location for the first Longevity AI Consortium in the UK because it has dedicated divisions and resources both for AI and for Longevity. Furthermore, being located in London, it is in an ideal physical location to engage in cross-sector and industry-academic collaboration.

AI LONGEVITY ACCELERATOR PROGRAM: 10 LONGEVITY INDUSTRY SECTORS



ALL-PARTY PARLIAMENTARY GROUP FOR LONGEVITY

The All Party Parliamentary Group (APPG) for Longevity was set up in March 2019 to address the scientific, technological and socio-economic issues relating to our ageing demographic and promote living younger, healthier and longer lives. The APPG is aiming to produce, with partners and experts, a draft National Strategy by end 2019 setting out what the United Kingdom needs to do to meet the goal set by Government of five more years of healthy life expectancy by 2035 (HLE + 5) and at the same time to close the large social gap in healthy life expectancy. Through an ambitious action plan in 2020, the APPG aims to turn the 'problem' of ageing into one of the most promising opportunities of the 21st century – and secure Britain's place as a global leader in longevity by providing access to the 'longevity dividend' to everyone equitably in society.

Executive Team of Longevity International UK



Eric Kihlstrom

Head of Industry
Collaboration



Tina Woods

CEO & Co-Founder
Secretariat Director



Dmitry Kaminskiy

Head of International
Cooperation Division




Deep Knowledge Group General Partner Dmitry Kaminskiy at the Official Lunch Event of the All-Party Parliamentary Group for Longevity In UK Parliament, alongside Rt Hon Damian Green MP (APPG Chair), The Lord Filkin CBE (Advisory Board Chair), Professor Andrew Scott (Advisory Board Member), Rt Hon Matt Hancock MP, Secretary of State for Health and Social Care, as well as Tina Woods (Co-Founder of the APPG for Longevity Secretariat) and Eric Kihlstrom (Head of Industry Collaboration for the APPG for Longevity Secretariat).



Longevity International UK is the
Secretariat for the All-Party
Parliamentary Group for Longevity

MEDIA LONGEVITY BOOK

***DEEP KNOWLEDGE
GROUP***



Upcoming Landmark Book by Dmitry Kaminskiy and Margareta Colangelo.

Longevity Industry 1.0 - Formatting the Biggest and Most Complex Industry in the Human History.





DeepTech Official LinkedIn Newsletter: Where Advanced Engineering Meets DeepTech Science.

The synergetic convergence of AI, Science, Advanced Engineering and DeepTech.




Longevity Official LinkedIn Newsletter: Where Technology Meets Precision Health.

Biomedicine Scientific Breakthroughs, Frontier Technologies, & Novel Financial Systems in the New Era of Longevity.



Defining the Biggest and Most Complex Industry in Human History


DMITRY
KAMINSKIY





MARGARETTA
COLANGELO

In *"Longevity Industry 1.0 - Defining the Biggest and Most Complex Industry in Human History"*, seasoned Longevity industry professionals Dmitry Kaminskiy and Margaretta Colangelo distill the complex assembly of deep market intelligence and industry knowledge that they have developed over the past 5 years into a full-scope understanding of the global Longevity Industry, showing the public exactly how they managed to define the overwhelmingly complex and multidimensional Longevity Industry for the first time, and how they created tangible framework for its systematization and forecasting.

The book features first of its kind coverage of entirely new segments and sectors of the rising Longevity Industry, including Longevity Politics and Governance, the Longevity Financial Industry (including coverage of AgeTech, WealthTech, FinTech, and the coming rise of new financial instruments and derivatives), the current state and forecasts on the Global Industrialization of Longevity to Scale, and an overview of the near-future trajectory of the Longevity Industry's evolution 2020- 2025.






2010-2020: Evolution of the Longevity Industry from Zero to 1.0

- The Industrialization of Longevity
- The Current State of Longevity Science, Business, Finance, and Practical Applications
- Longevity Becomes National Priority Item for the Strategic Agenda of Progressive Governments
- Transforming the Challenge and Deficit of Aging into the Opportunity and Asset of Longevity
- Defining and De-Risking: Hype vs. Reality


2020-2025: DeepTech Engineering The Accelerated Trajectory of Human Longevity - The Blueprint and Pathway from 1.0 to 2.0

- Global Industrialization of Longevity to Scale
- The Evolution from Longevity Start-ups to Multi-Trillion Dollar Longevity Corporations
- The Disruption of BioTech and Healthcare by Novel AI-Driven InvestTech Solutions
- How AI-Driven Preventive Medicine will Disrupt BioTech and Healthcare Industries
- Novel Financial Instruments and InvestTech Solutions
- The Rise of Progressive Longevity MegaHubs



"Deep Knowledge Ventures, a Hong Kong-based venture capital fund that invests in life sciences, cancer research, age-related diseases and regenerative medicine has appointed an artificial intelligence algorithm called VITAL (Validating Investment Tool for Advancing Life Sciences) to its board of directors.

Klaus Schwab "The Fourth Industrial Revolution", page 149



"In May 2014 Deep Knowledge Ventures – a Hong Kong venture-capital firm specialising in regenerative medicine – broke new ground by appointing an algorithm called VITAL to its board. VITAL makes investment recommendations by analysing huge amounts of data on the financial situation, clinical trials and intellectual property of prospective companies. Like the other five board members, the algorithm gets to vote on whether the firm makes an investment in a specific company or not."

Yuval Noah Harari "Homo Deus: A Brief History of Tomorrow", page 437



FINANCIAL TIMES



NIKKEI
ASIAN REVIEW

Esquire

Forbes

HUFFPOST

Daily Mail

The
Guardian



"In a world first, Japanese venture capital firm Deep Knowledge recently named an artificial intelligence (AI) to its board of directors. The robot, named Vital, was chosen for its ability to pick up on market trends 'not immediately obvious to humans'"



"For Deep Knowledge Ventures, the Hong Kong-based venture firm that added a machine learning algorithm named VITAL to its board in 2014, it was about adding a tool to analyse market data around investment opportunities."



"The firm, Deep Knowledge Ventures (DKV), which invests in companies researching treatments for age-related diseases and regenerative medicine, uses the algorithm to analyze financing trends to make investment recommendations in the life sciences sector."



"Deep Knowledge Ventures said that the AI would help make financial and business decisions, help lead its research into biotechnology and regenerative medicine, and would act as an "equal member of the board".



"Artificial intelligence gets a seat in the boardroom. Hong Kong venture capitalist sees AI running Asian companies within 5 years."



"" The One Billion Retired People Globally are a Multi-Trillion Dollar Opportunity for Business" - Dmitry Kaminskiy for Financial Times



An Insight Of AI's Penetration In Drug Development Market. Thanks to Deep Knowledge Ventures which a couple of days ago updated their research data, we took the opportunity to delve into the latest developments of this market.



"A venture capital firm has appointed a computer algorithm to its board of directors. According to Deep Knowledge Ventures, Vital has already approved two investment decisions. The software was developed by UK-based Aging Analytics."

CONFERENCES

*DEEP KNOWLEDGE
GROUP*

DEEP KNOWLEDGE GROUP / INTERNATIONAL LONGEVITY POLICY AND GOVERNANCE SUMMIT 2019



International Longevity Policy and Governance Summit

November 12th 2019, 09:00 - 13:45
King's College, London, UK

Longevity International UK is proud to be launching the world's first international, cross-border, cross-sector summit on the current state of International Longevity Policy and Governance as part of London Longevity Week 2019, establishing a dedicated forum that brings together policy experts, representatives of government bodies, departments, healthcare and finance ministries, executives of healthcare and financial corporations to discuss international Government-led Longevity development, to network with like-minded professionals and organizations, and to work toward establishing effective and actionable collaborative initiatives.




Tina Woods

Longevity International UK



Dmitry Kaminskiy

Aging Analytics Agency



Eric Kihlstrom

Longevity International UK



Rt Hon Damian Green MP

All-Party Parliamentary
Group for Longevity



Lord Geoff Filkin CBE

All-Party Parliamentary
Group for Longevity



Dr Charles Alessi

HIMSS



Julia Randell-Khan

Center on Longevity,
Stanford University



Professor, Kenji Shubuya

Institute for Population
Health, Kings College
London.



Mike Hodin

Global Coalition on Aging
(TBD)



Sergey Young

Longevity Vision Fund



INVITATION FOR

Government Representatives
Foreign Ambassadors
Policy Experts
Healthcare & Financial Executives
NGOs, NonProfits, Think-Tanks

“Living Longer, Healthier and Productively for Global Prosperity”

Building Cross-Country and Cross-Sector
Bridges for Longevity Politics and
Governance Initiatives



Supporting Partners

Longevity International Policy and Governance Summit is supported by:




Longevity International UK is the Secretariat for the All-Party Parliamentary Group for Longevity.






The inaugural, exclusive and invitation-only AI for Longevity Summit, organized by the AI Longevity Consortium at King's College in London, brings together leading scientists, industry players, and experts to present and discuss the cutting-edge of Artificial Intelligence for ageing research and the practical implementation of longevity technologies for preventive medicine and precision health. The Summit to be held at the Guy's campus of King's College on November 12th, 2019. It will be the first in a series of conferences, which we expect to become the world-leading forum on AI for Longevity. The next two events in the series will be held in 2020 in London, UK and Zurich, Switzerland.



Richard Siow
 AI Longevity Consortium at King's College London



Dmitry Kaminskiy
 Longevity.Capital



Craig Rhodes
 NVIDIA



Lance Kawaguchi
 HSBC



Al-Noor Ramji
 Prudential



Stephen Wang
 Huawei



Alex Zhavoronkov
 Insilico Medicine



Jorge Cardoso
 King's College London AI Center




Reza Razavi
 King's College London






Benjamin Swerner
 Juvenescence

Paradigm Shift from Treatment to Prevention



The New Frontier - from Precision Medicine to Precision Health





CONTACT US

info@dkv.global

www.dkv.global

“Knowledge” is Power

“Deep Knowledge” is Transcending Power